Product Images Toviaz

This appears to be the label information for a medication called Toviaz 4G, which is distributed by Ngslclmswvm Care. The NDC and lot/expiry information are also provided on the label. The last line may be a batch or code number.*

This is a description of a medication called Toviaz BHG Tab. It is distributed by Physicians Total Care and has an NDC code of 54868-6175-0. The medication comes from lot number 0060 and has an expiration date of 01460. The rest of the text is not readable.*

The text describes a graph displaying the change in number of micturitions per 24 hours over the course of 12 weeks in Study 1. The graph shows the results for a placebo group (N=279) and a group taking Toviaz at either 4mg or 8mg doses. The mean change from baseline is plotted against weeks 2, 8, and 12.*

This is a chart displaying the change in urge incontinence episodes over a study of 12 weeks. The horizontal axis shows the number of weeks, and the vertical axis shows the change from baseline in the number of urge incontinence episodes per 24 hours. There are three treatment groups represented: a placebo group (N=211), a Toviaz 4mg group (N=139), and a Toviaz 8mg group (N=223).*

The text describes the mean change from baseline in the number of micturitions per 24 hours in Study 2. The change observed was -0.5 micturitions per 24 hours. There is also a graph (Figure 3) showing the change in the number of micturitions over time (weeks 2, 8, and 12) for the placebo group (N=266), the Toviazdmg group (N=267), and the Tovazsmg group (N=267).*

This is a graph that shows the change in urge incontinence episodes per 24 hours over a period of 12 weeks in Study 2. The graph includes three treatment groups: a Placebo group (205 participants), a Toviazdmg group (228 participants), and a Tovazsmg group (218 participants). The x-axis shows the weeks, and the y-axis shows the number of incontinence episodes. At Week 0, all groups had a similar number of incontinence episodes per 24 hours (around 0.0). Over the course of 12 weeks, there was a decrease in incontinence episodes in all three groups, with the Tovazsmg group showing the most significant reduction.*

This appears to be an error. The text is not readable.*